Zydus Cadila Healthcare Ltd - Product Pipeline Review - 2016

Published: Dec, 2016 | Pages: 84 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Zydus Cadila Healthcare Ltd - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Zydus Cadila Healthcare Ltd - Product Pipeline Review - 2016', provides an overview of the Zydus Cadila Healthcare Ltd's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Zydus Cadila Healthcare Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Zydus Cadila Healthcare Ltd
- The report provides overview of Zydus Cadila Healthcare Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Zydus Cadila Healthcare Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Zydus Cadila Healthcare Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Zydus Cadila Healthcare Ltd's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Zydus Cadila Healthcare Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Zydus Cadila Healthcare Ltd's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Zydus Cadila Healthcare Ltd Snapshot 9
Zydus Cadila Healthcare Ltd Overview 9
Key Facts 9
Zydus Cadila Healthcare Ltd - Research and Development Overview 10
Key Therapeutic Areas 10
Zydus Cadila Healthcare Ltd - Pipeline Review 15
Pipeline Products by Stage of Development 15
Pipeline Products - Monotherapy 16
Pipeline Products - Combination Treatment Modalities 17
Pipeline Products - Partnered Products 18
Partnered Products/Combination Treatment Modalities 19
Zydus Cadila Healthcare Ltd - Pipeline Products Glance 20
Zydus Cadila Healthcare Ltd - Late Stage Pipeline Products 20
Pre-Registration Products/Combination Treatment Modalities 20
Phase III Products/Combination Treatment Modalities 21
Zydus Cadila Healthcare Ltd - Clinical Stage Pipeline Products 22
Phase II Products/Combination Treatment Modalities 22
Phase I Products/Combination Treatment Modalities 23
Zydus Cadila Healthcare Ltd - Early Stage Pipeline Products 24
Preclinical Products/Combination Treatment Modalities 24
Discovery Products/Combination Treatment Modalities 25
Zydus Cadila Healthcare Ltd - Unknown Stage Pipeline Products 26
Unknown Products/Combination Treatment Modalities 26
Zydus Cadila Healthcare Ltd - Drug Profiles 27
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
(diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
(diphtheria + tetanus) vaccine - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
(measles + mumps + rubella + varicella) vaccine - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
(measles + mumps + rubella) vaccine - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
bevacizumab biosimilar - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Biosimilar 1 for Nephrology, Acute Myocardial Infarction and Oncology - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Biosimilar 2 for Diabetes, Infertility and Rheumatoid Arthritis - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Biosimilar 3 for Rheumatoid Arthritis, Acute Myocardial Infarction, Oncology and Inflammation - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Biosimilar 4 for Acute Myocardial Infarction, Infertility, Oncology and Thrombosis - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Biosimilar 5 for Infertility and Oncology - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Biosimilar 6 for Infertility, Oncology and Immunology - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Biosimilar 7 for Infertility, Immunology and Oncology - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Crimean-Congo hemorrhagic fever vaccine - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Ebola vaccine - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Haemophilus influenzae B vaccine - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
hepatitis A vaccine - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
hepatitis B vaccine - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
hepatitis E vaccine - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
human papillomavirus vaccine - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
interferon beta-1b - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Japanese encephalitis vaccine - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
MAb-1 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
MAb-2 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
MAb-3 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
MAb-4 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
malaria vaccine - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
measles vaccine - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
PEG-EPO - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Rabimabs - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
rituximab biosimilar - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
saroglitazar - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
tetanus vaccine - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
typhoid vaccine - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
ZYAN-1 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
ZYDPLA-1 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
ZYH-7 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
ZYTP-1 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Zydus Cadila Healthcare Ltd - Pipeline Analysis 71
Zydus Cadila Healthcare Ltd - Pipeline Products by Target 71
Zydus Cadila Healthcare Ltd - Pipeline Products by Route of Administration 73
Zydus Cadila Healthcare Ltd - Pipeline Products by Molecule Type 74
Zydus Cadila Healthcare Ltd - Pipeline Products by Mechanism of Action 75
Zydus Cadila Healthcare Ltd - Dormant Projects 77
Zydus Cadila Healthcare Ltd - Company Statement 78
Zydus Cadila Healthcare Ltd - Locations And Subsidiaries 80
Head Office 80
Other Locations & Subsidiaries 80
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 83
Disclaimer 84

List of Tables

Zydus Cadila Healthcare Ltd, Key Facts 9
Zydus Cadila Healthcare Ltd - Pipeline by Indication, 2016 11
Zydus Cadila Healthcare Ltd - Pipeline by Stage of Development, 2016 15
Zydus Cadila Healthcare Ltd - Monotherapy Products in Pipeline, 2016 16
Zydus Cadila Healthcare Ltd - Combination Treatment Modalities in Pipeline, 2016 17
Zydus Cadila Healthcare Ltd - Partnered Products in Pipeline, 2016 18
Zydus Cadila Healthcare Ltd - Partnered Products/ Combination Treatment Modalities, 2016 19
Zydus Cadila Healthcare Ltd - Pre-Registration, 2016 20
Zydus Cadila Healthcare Ltd - Phase III, 2016 21
Zydus Cadila Healthcare Ltd - Phase II, 2016 22
Zydus Cadila Healthcare Ltd - Phase I, 2016 23
Zydus Cadila Healthcare Ltd - Preclinical, 2016 24
Zydus Cadila Healthcare Ltd - Discovery, 2016 25
Zydus Cadila Healthcare Ltd - Unknown, 2016 26
Zydus Cadila Healthcare Ltd - Pipeline by Target, 2016 72
Zydus Cadila Healthcare Ltd - Pipeline by Route of Administration, 2016 73
Zydus Cadila Healthcare Ltd - Pipeline by Molecule Type, 2016 74
Zydus Cadila Healthcare Ltd - Pipeline Products by Mechanism of Action, 2016 76
Zydus Cadila Healthcare Ltd - Dormant Developmental Projects,2016 77
Zydus Cadila Healthcare Ltd, Other Locations 80
Zydus Cadila Healthcare Ltd, Subsidiaries 81